Synopsis
Synopsis
0
JDMF
0
KDMF
0
VMF
0
FDF
0
Australia
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. Acetic Acid, Calcium Salt
2. Acetic Acid, Calcium Salt (2:1)
3. Phoslo
1. 62-54-4
2. Calcium Diacetate
3. Acetic Acid, Calcium Salt
4. Lime Acetate
5. Phoslo
6. Lime Pyrolignite
7. Acetate Of Lime
8. Brown Acetate
9. Acetic Acid Calcium Salt
10. Gray Acetate Of Lime
11. Brown Acetate Of Lime
12. Phoslyra
13. Calcium;diacetate
14. Calcium Ethanoate
15. Fema No. 2228
16. Calcarea Acetica
17. Calcium(ii) Acetate
18. Acetic Acid, Calcium Salt (2:1)
19. Calcium Acetate Anhydrous
20. Calcium Acetate, Anhydrous
21. Chebi:3310
22. Ins No.263
23. Y882yxf34x
24. Teltozan
25. Sorbo-calcion
26. Vinegar Salts
27. Gray Acetate
28. Ins-263
29. Phoslo Gelcaps
30. Calcium Di(acetate)
31. E-263
32. Ca(oac)2
33. Eliphos
34. Sanopan
35. Ccris 4921
36. Hsdb 928
37. Einecs 200-540-9
38. Calcium Acetate [usp:jan]
39. Unii-y882yxf34x
40. Ai3-02903
41. Calcium Acetate Salt
42. Phoslo (tn)
43. Calcium Acetate, Fcc
44. Calcium Acetate (usp)
45. Ec 200-540-9
46. Calcium Acetate 23% 10m
47. Schembl23872
48. Calcium Acetate [ii]
49. Calcium Acetate [mi]
50. Calcium Acetate [fcc]
51. Calcium Acetate [fhfi]
52. Calcium Acetate [hsdb]
53. Calcium Acetate [inci]
54. Calcarea Acetica [hpus]
55. Calcium Acetate [vandf]
56. Calcium Acetate [mart.]
57. Chembl1200800
58. Dtxsid0020234
59. Calcium Acetate [usp-rs]
60. Calcium Acetate [who-dd]
61. Calcium Acetate (fragrance Grade)
62. Amy23411
63. Mfcd00012448
64. Calcium Acetate [orange Book]
65. Akos015904560
66. Calcium Acetate [ep Monograph]
67. Calcium Acetate [usp Monograph]
68. Db00258
69. E263
70. Ft-0623376
71. Ft-0623377
72. D00931
73. Calcium Acetate, Anhydrous [ep Impurity]
74. Cis,cis-1,3,5-cyclohexanetricarboxylicacid
75. Q409251
76. Calcium Diacetate, Cac - Acetic Acid, Calcium Salt
77. J-519530
Molecular Weight | 158.17 g/mol |
---|---|
Molecular Formula | C4H6CaO4 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 0 |
Exact Mass | 157.9891995 g/mol |
Monoisotopic Mass | 157.9891995 g/mol |
Topological Polar Surface Area | 80.3 Ų |
Heavy Atom Count | 9 |
Formal Charge | 0 |
Complexity | 25.5 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
1 of 6 | |
---|---|
Drug Name | Calcium acetate |
PubMed Health | Calcium Acetate (By mouth) |
Drug Classes | Calcium Supplement, Phosphate Binder |
Drug Label | Each white, round tablet (stamped CYP910) contains 667 mg calcium acetate, USP (anhydrous; Ca(CH3COO)2; MW=158.17 grams) equal to 169 mg (8.45 mEq) calcium, polyethylene glycol 8000 NF; sodium lauryl sulfate, NF; and crospovidone, NF. ELIPHOS... |
Active Ingredient | Calcium acetate |
Dosage Form | Tablet; Capsule |
Route | Oral |
Strength | eq 169mg calcium |
Market Status | Prescription |
Company | Amneal Pharms; Paddock; Invagen Pharms; Roxane |
2 of 6 | |
---|---|
Drug Name | Phoslo gelcaps |
Active Ingredient | Calcium acetate |
Dosage Form | Capsule |
Route | Oral |
Strength | eq 169mg calcium |
Market Status | Prescription |
Company | Fresenius Medcl |
3 of 6 | |
---|---|
Drug Name | Procalamine |
Active Ingredient | calcium acetate; sodium chloride; magnesium acetate; sodium acetate; phosphoric acid; glycerin; potassium chloride; Amino acids |
Dosage Form | Injectable |
Route | Injection |
Strength | 200mg/100ml; 150mg/100ml; 26mg/100ml; 54mg/100ml; 120mg/100ml; 3gm/100ml; 41mg/100ml; 3% |
Market Status | Prescription |
Company | B Braun |
4 of 6 | |
---|---|
Drug Name | Calcium acetate |
PubMed Health | Calcium Acetate (By mouth) |
Drug Classes | Calcium Supplement, Phosphate Binder |
Drug Label | Each white, round tablet (stamped CYP910) contains 667 mg calcium acetate, USP (anhydrous; Ca(CH3COO)2; MW=158.17 grams) equal to 169 mg (8.45 mEq) calcium, polyethylene glycol 8000 NF; sodium lauryl sulfate, NF; and crospovidone, NF. ELIPHOS... |
Active Ingredient | Calcium acetate |
Dosage Form | Tablet; Capsule |
Route | Oral |
Strength | eq 169mg calcium |
Market Status | Prescription |
Company | Amneal Pharms; Paddock; Invagen Pharms; Roxane |
5 of 6 | |
---|---|
Drug Name | Phoslo gelcaps |
Active Ingredient | Calcium acetate |
Dosage Form | Capsule |
Route | Oral |
Strength | eq 169mg calcium |
Market Status | Prescription |
Company | Fresenius Medcl |
6 of 6 | |
---|---|
Drug Name | Procalamine |
Active Ingredient | calcium acetate; sodium chloride; magnesium acetate; sodium acetate; phosphoric acid; glycerin; potassium chloride; Amino acids |
Dosage Form | Injectable |
Route | Injection |
Strength | 200mg/100ml; 150mg/100ml; 26mg/100ml; 54mg/100ml; 120mg/100ml; 3gm/100ml; 41mg/100ml; 3% |
Market Status | Prescription |
Company | B Braun |
... Used to restrict phosphate absorption in patients with chronic renal failure and oxalate absorption in patients with inflammatory bowel disease.
Hardman, J.G., L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Goodman (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, 1996., p. 1523
Calcium acetate is indicated in patients with end-stage renal failure to lower serum phosphate concentrations. It does not promote aluminum absorption. /Included in US product labeling/
USP. Convention. USPDI - Drug Information for the Health Care Professional. 19th ed. Volume I.Micromedex, Inc. Englewood, CO., 1999. Content Prepared by the U.S. Pharmacopieal Convention, Inc., p. 719
Except under special circumstances, this medication /calcium acetate/ should not be used when the following medical problem exists: hypercalcemia (calcium acetate may exacerbate the condition).
USP. Convention. USPDI - Drug Information for the Health Care Professional. 19th ed. Volume I.Micromedex, Inc. Englewood, CO., 1999. Content Prepared by the U.S. Pharmacopieal Convention, Inc., p. 719
Concurrent use /with digitalis glycosides/ is not recommended because calcium acetate may cause hypercalcemia, which could precipitate cardiac arrhythmias.
USP. Convention. USPDI - Drug Information for the Health Care Professional. 19th ed. Volume I.Micromedex, Inc. Englewood, CO., 1999. Content Prepared by the U.S. Pharmacopieal Convention, Inc., p. 719
Calcium acetate is one of a number of calcium salts used to treat hyperphosphatemia (too much phosphate in the blood) in patients with kidney disease.
FDA Label
Patients with advanced renal insufficiency (creatinine clearance less than 30 ml/min) exhibit phosphate retention and some degree of hyperphosphatemia. The retention of phosphate plays a pivotal role in causing secondary hyperparathyroidism associated with osteodystrophy, and soft-tissue calcification. The mechanism by which phosphate retention leads to hyperparathyroidism is not clearly delineated. Therapeutic efforts directed toward the control of hyperphosphatemia include reduction in the dietary intake of phosphate, inhibition of absorption of phosphate in the intestine with phosphate binders, and removal of phosphate from the body by more efficient methods of dialysis. The rate of removal of phosphate by dietary manipulation or by dialysis is insufficient. Dialysis patients absorb 40% to 80% of dietary phosphorus. Therefore, the fraction of dietary phosphate absorbed from the diet needs to be reduced by using phosphate binders in most renal failure patients on maintenance dialysis. Calcium acetate when taken with meals combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders. Calcium acetate is highly soluble at neutral pH, making the calcium readily available for binding to phosphate in the proximal small intestine.
Chelating Agents
Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS. (See all compounds classified as Chelating Agents.)
V - Various
V03 - All other therapeutic products
V03A - All other therapeutic products
V03AE - Drugs for treatment of hyperkalemia and hyperphosphatemia
V03AE07 - Calcium acetate
Absorption
40% is absorbed in the fasting state and approximately 30% is absorbed in the nonfasting state following oral administration.
Route of Elimination
Calcium acetate when taken with meals, combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces.
Calcium acetate and other calcium salts are phosphate binders. They work by binding with the phosphate in the food you eat, so that it is eliminated from the body without being absorbed.
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Calcium Acetate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Calcium Acetate, including repackagers and relabelers. The FDA regulates Calcium Acetate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Calcium Acetate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Calcium Acetate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Calcium Acetate supplier is an individual or a company that provides Calcium Acetate active pharmaceutical ingredient (API) or Calcium Acetate finished formulations upon request. The Calcium Acetate suppliers may include Calcium Acetate API manufacturers, exporters, distributors and traders.
click here to find a list of Calcium Acetate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Calcium Acetate DMF (Drug Master File) is a document detailing the whole manufacturing process of Calcium Acetate active pharmaceutical ingredient (API) in detail. Different forms of Calcium Acetate DMFs exist exist since differing nations have different regulations, such as Calcium Acetate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Calcium Acetate DMF submitted to regulatory agencies in the US is known as a USDMF. Calcium Acetate USDMF includes data on Calcium Acetate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Calcium Acetate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Calcium Acetate suppliers with USDMF on PharmaCompass.
A Calcium Acetate CEP of the European Pharmacopoeia monograph is often referred to as a Calcium Acetate Certificate of Suitability (COS). The purpose of a Calcium Acetate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Calcium Acetate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Calcium Acetate to their clients by showing that a Calcium Acetate CEP has been issued for it. The manufacturer submits a Calcium Acetate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Calcium Acetate CEP holder for the record. Additionally, the data presented in the Calcium Acetate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Calcium Acetate DMF.
A Calcium Acetate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Calcium Acetate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Calcium Acetate suppliers with CEP (COS) on PharmaCompass.
A Calcium Acetate written confirmation (Calcium Acetate WC) is an official document issued by a regulatory agency to a Calcium Acetate manufacturer, verifying that the manufacturing facility of a Calcium Acetate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Calcium Acetate APIs or Calcium Acetate finished pharmaceutical products to another nation, regulatory agencies frequently require a Calcium Acetate WC (written confirmation) as part of the regulatory process.
click here to find a list of Calcium Acetate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Calcium Acetate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Calcium Acetate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Calcium Acetate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Calcium Acetate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Calcium Acetate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Calcium Acetate suppliers with NDC on PharmaCompass.
Calcium Acetate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Calcium Acetate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Calcium Acetate GMP manufacturer or Calcium Acetate GMP API supplier for your needs.
A Calcium Acetate CoA (Certificate of Analysis) is a formal document that attests to Calcium Acetate's compliance with Calcium Acetate specifications and serves as a tool for batch-level quality control.
Calcium Acetate CoA mostly includes findings from lab analyses of a specific batch. For each Calcium Acetate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Calcium Acetate may be tested according to a variety of international standards, such as European Pharmacopoeia (Calcium Acetate EP), Calcium Acetate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Calcium Acetate USP).
LOOKING FOR A SUPPLIER?